Brave new drugs, enduring old skills: why surgery still matters in the cardiac myosin inhibitor era
Authors:
Open Access
- 23 January 2026
- journal article
- editorial
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 42 (2) , 151-154
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 WeeksCirculation, 2023
- Impact of Hospital Volume on Outcomes of Septal Myectomy for Hypertrophic CardiomyopathyThe Annals of Thoracic Surgery, 2022
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic CardiomyopathyCirculation, 2020
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Mavacamten Treatment for Obstructive Hypertrophic CardiomyopathyAnnals of Internal Medicine, 2019
- Genotype and Lifetime Burden of Disease in Hypertrophic CardiomyopathyCirculation, 2018
- Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experienceAnnals of Cardiothoracic Surgery, 2017
- Surgery Insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experienceNature Clinical Practice Cardiovascular Medicine, 2007
- Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2005
- Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic CardiomyopathyNew England Journal of Medicine, 2003